Table 3. Exploratory Pharmacokinetic Summary From Patients Receiving Vatalanib Alone (Day 14), Vatalanib After Everolimus Started (Day 29), and Everolimus With Vatalanib (Day 29).

Agent	Vatalanib Alone	Vatalanib + Everolimus	Everolimus
	Mean ± SD	Mean ± SD	Mean ± SD
t1/2(h)	6.32 ± 4.46	5.71 ± 3.06	14.0 ± 2.5
tmax(h)	2.00 (1.08-6.08)a	2.08 (1.00-4.08)a	1.31 (0.73-17.7)a
Cssmax(ng/mL)	4825 ± 2910	3963 ± 1861	48.5 ± 14.8
AUC (ng·h/mL)	26,384 ± 13,201	21,626 ± 9778	377 ±117
Cssavg(ng/mL)	1099 ± 551	901 ± 403	15.7 ± 4.9
CLss/F (L/h)	53.7 ± 38.7	53.7 ± 38.7	14.3 ± 3.7
Vz/F (L)	488 ± 481	488 ± 481	216 ± 74

Abbreviations: AUC = area under the plasma concentration vs. time curve; CL/F = oral clearance; Css_avg = steady-state plasma concentration; Css_max = value of maximum plasma concentration; t¹/₂ = terminal phase rate constant and half-life; t_max = time to peak concentration; Vz/F = area volume of distribution after oral dosing.

^aMedian.